Strategies to Secure Access to Generic HCV Medicines

Strategies to Secure Access to Generic HCV Medicines

Source: http://www.msfaccess.org

MSF is in the process of starting to treat people who are living with hepatitis C virus (HCV) in at least nine countries, and therefore is in need of affordable access to direct acting antiviral (DAA) treatments, including those marketed by Gilead Sciences (Gilead) and Bristol-Myers Squibb (BMS).

There are legal means that countries excluded from voluntary licenses can consider using to get access to affordable generic versions of DAAs. Countries must also overcome regulatory barriers that may keep both branded and generic versions of DAAs from entering the market.

This document offers guidance to policy makers to enable access to these medicines to scale up HCV treatment..read the full document

/ News

Share the Post